This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 5 EPO patents. Top assignee: Novartis Vaccines & Diagnostics, Gmbh. Active years: 2012-2014.
Company Filing History:
Years Active: 2012-2014
Title: Isabel Zaror: Innovator in Antagonist Anti-CD40 Monoclonal Antibodies
Introduction
Isabel Zaror is a prominent inventor based in El Cerrito, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of antagonist anti-CD40 monoclonal antibodies. With a total of 2 patents, her work focuses on innovative therapeutic methods for treating diseases mediated by CD40 signaling.
Latest Patents
Zaror's latest patents include compositions and methods for therapy that utilize antagonist anti-CD40 monoclonal antibodies. These methods involve administering a therapeutically effective amount of an antagonist anti-CD40 antibody or its antigen-binding fragment to patients in need. The antibodies are designed to be free of significant agonist activity while exhibiting antagonist activity when binding to CD40 antigens on human CD40-expressing cells. This antagonist activity is crucial as it beneficially inhibits the proliferation and differentiation of human CD40-expressing cells, such as B cells.
Career Highlights
Throughout her career, Isabel Zaror has worked with notable companies in the biotechnology sector. She has been associated with Novartis Vaccines & Diagnostics and Xoma Technology Ltd. Her experience in these organizations has contributed to her expertise in developing innovative therapeutic solutions.
Collaborations
Zaror has collaborated with esteemed colleagues, including Li Long and Mohammad Luqman. These partnerships have further enhanced her research and development efforts in the field of monoclonal antibodies.
Conclusion
Isabel Zaror is a trailblazer in the development of antagonist anti-CD40 monoclonal antibodies, with a focus on innovative therapies for diseases related to CD40 signaling. Her contributions to biotechnology continue to impact the field positively.